In coronary bypass patients, the proportion spending at least half of the study period in the target glucose range did not differ significantly between exenatide and insulin therapy.
In plain wordsAfter coronary bypass, exenatide and insulin did not significantly differ in the share spending at least half of study time within the glucose target.
- Peptide
- Exenatide (exendin-4)
- Outcome
- No significant changePatients with at least half of study time in glucose target
- Study
n = 104
- Comparator
- Insulin therapy
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 0.05 µg/min for 1 hour, then 0.025 µg/min · intravenousAs given in this study (human).
Measurements
- Patients with at least 50% of study period in target range
- 72%
- exenatide group (38 patients)
- Patients with at least 50% of study period in target range
- 80%
- control group (41 patients)
- Odds ratio
- 0.85 ratio
- exenatide versus control
Source sentences
The primary outcome was observed in 38 (72%) patients in the exenatide group and in 41 (80%) patients in the control group (odds ratio [95% CI] = 0.85 [0.34 to 2.11]; P = 0.30).
3 context sentences(design, population, supporting numbers)
The primary outcome was the proportion of patients who spent at least 50% of the study period within the target range.
Patients more than 18 yr old admitted for elective coronary artery bypass grafting were included in a phase II/III nonblinded randomized superiority trial.
Two groups were compared: the exenatide group, receiving exenatide (1-h bolus of 0.05 µg/min followed by a constant infusion of 0.025 µg/min), and the control group, receiving insulin therapy.